Director, Clinical Science

Olema Oncology is  a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with  breast cancer  and beyond.   It’s  an exciting time to be part of Team Olema ,  with   our transfor mation into a fully   integrated oncology company well underway ,  t op-line data from our lead program expected  later  this  year ,   and our first potential commercial launch on the horizon. Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant has the potential to transform the metastatic breast cancer treatment paradigm and access a $15 billion global market opportunity. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently reported encouraging Phase 1 monotherapy data from this program across multiple solid tumor types and are advancing patient enrollment in the ongoing combination arms in MBC. Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and a passionate team dedicated to helping the patients we serve feel better, longer. We possess a deep commitment to our shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution.  Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day. If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together –  for  our patients, for your career,  and  for  what’s  beyond . About the Role >>> Director, Clinical Science   As the Director, Clinical Science   reporting to the Vice President, Clinical Science, you will play a key role in one of our ongoing clinical studies. You will work collaboratively in a multi-disciplinary team setting including Clinical Operations, Medical Monitors, Data Management, Biostatistics, Clinical Pharmacology, Regulatory and Program Management, in the planning, conduct and analysis of clinical trials.  Your job contributes to and supports Olema’s mission of developing therapies that offer the potential to improve outcomes for women living with cancer.  This role is based out of our San Francisco, CA or Cambridge, MA office and will require up to 20%   travel.  Your work will  primarily  encompass:  Writing of technical and clinical documents including protocols, amendments, investigator’s brochures, and the clinical sections of regulatory documents  Working with the study team to identify and track any potential safety events within a given trial   Interacting with investigators and thought leaders in oncology to facilitate the design of clinical synopses and protocols  Evaluate the safety, pharmacology, and efficacy of ongoing studies in close collaboration with the medical monitor and the safety, pharmacology and clinical operations teams Organizing and performing the study level and individual subject level analysis of the clinical trial data to gain insights and develop strategies for the clinical study report (CSR) writing  Contributing to the writing and/or review product specific abstracts, publications and supporting the development of presentations for scientific meetings  Maintaining clinical and technical expertise in the therapeutic area of oncology  Attending scientific meetings pertinent to clinical science activities  And will also include:  Collaborating with the Medical Monitor on review of enrollment packets, clinical development plans and scientific presentations  Collaborating with Clinical Operations and other internal study teams to develop Informed Consent Forms, Case Report Forms and CRF instructions  Participating in ongoing clinical data review in collaboration with a cross functional team  Collaborating with Clinical Operations and other team members in the development of agendas, training materials and presentation for site visits, investigator meetings and other study related activities  Ensuring adherence to Olema’s Standard Operation Procedures and values, and maintaining the highest level of ethical behavior by leading by example  Ideal Candidate Profile >>>    A love of challenging, important work.  We are a pragmatic team, driven to imagine and develop meaningful therapies for improving lives. All employees within our company play a unique and crucial role in our success, both in accomplishing our mission and building a positive company culture. As such, we are looking for someone with the right combination of  knowledge ,  experience , and  attributes  for this role.  Knowledge:   Advanced degree such as a PhD or PharmD is required Experience in oncology clinical development is required  Comprehensive knowledge of oncology clinical trial implementation and drug development process  Demonstrated understanding of the clinical drug development process to execute drug developme